Home > Insider Trading > Filing (0001562180-18-004207)

Filing Details

Accession Number:: 0001562180-18-004207
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-10-10 16:20:48
Reporting Period:: 2018-10-08

Accepted Time:: 2018-10-10 16:20:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1590877	Regenxbio Inc.	RGNX	Biological Products, (No Disgnostic Substances) (2836)	471851754

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1701180	Olivier Danos	C/O Regenxbio Inc. 9600 Blackwell Road, Suite 210 Rockville MD 20850	Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-10-08	20,000	$20.35	20,000	No	4	M	Direct
Common Stock	Disposition	2018-10-08	3,500	$62.79	16,500	No	4	S	Direct
Common Stock	Disposition	2018-10-08	12,284	$63.73	4,216	No	4	S	Direct
Common Stock	Disposition	2018-10-08	4,000	$64.78	216	No	4	S	Direct
Common Stock	Disposition	2018-10-08	216	$65.60	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2018-10-08	20,000	$0.00	20,000	$20.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
80,000		2027-03-26	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $62.31 to $63.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $63.35 to $64.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $64.36 to $65.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $65.40 to $65.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.